Retrospective series on ncRCC including papillary, chRCC, unclassified, CDC, Xp11 translocation, and ccRCC with sarcomatoid differentiation treated with anti PD-1 or PDL-1, alone or in combination with cytotoxic T-lymphocyte associated protein-4 (CTLA-4), reported ORR of 19–20% [50,51]. This evidence concerns the gene PDCD1 and chromophobe renal cell carcinoma.